Norethindrone vs Hormonal IUD (Mirena/Kyleena): Side-Effect Profile Head-to-Head

What Are These Two Progestins, and Why Does the Delivery Route Matter?

Both options deliver a synthetic progestin, but they do so in fundamentally different ways, and that difference drives almost every side-effect distinction you will read about below.

Norethindrone acetate (NETA) is swallowed as a tablet. It enters your bloodstream fully, circulates throughout your body, and affects tissues from your brain to your bones to your skin. The mini-pill dose is 0.35 mg daily for contraception. For heavy menstrual bleeding (HMB) or HRT progesterone add-back, doses run 5 mg daily or higher. Because NETA is a 19-nortestosterone derivative, it carries a mild androgenic signature, meaning it can behave a little like testosterone in some tissues.

The levonorgestrel IUD sits inside the uterine cavity and releases hormone directly into the endometrium. Mirena releases approximately 20 mcg/day initially, falling to roughly 10 mcg/day by year five. Kyleena releases about 17.5 mcg/day initially, declining to approximately 7.4 mcg/day by year five. These are tiny systemic doses. Most of the progestin effect stays local, inside the uterus, which is exactly why the uterine side effects are dramatic (amenorrhea, light spotting) while systemic effects are much milder compared to oral routes.

Knowing this distinction upfront makes the rest of the comparison logical rather than arbitrary.

Bleeding Side Effects: Where the Difference Is Largest

What to Expect on Norethindrone

Norethindrone at mini-pill doses (0.35 mg) commonly causes irregular, unpredictable spotting, particularly in the first three to six months. At HMB doses (5 mg), it suppresses the endometrium more aggressively, but irregular breakthrough bleeding still occurs in a meaningful proportion of users. The Cochrane review of progestins for HMB found that oral norethindrone reduced menstrual blood loss compared to placebo, but the reduction was substantially smaller than what is achieved with a levonorgestrel IUD.

Cycle unpredictability is one of the main reasons women stop norethindrone within the first year.

What to Expect on an LNG-IUD

The levonorgestrel IUD has the most dramatic effect on uterine bleeding of any reversible method. In the landmark NEJM 2013 trial (Gupta et al.), women with HMB randomized to the LNG-IUS had significantly greater reductions in menstrual blood loss and significantly better quality-of-life scores at 24 months compared with women assigned to usual medical care (which included oral progestins, tranexamic acid, and mefenamic acid). The LNG-IUD group also had lower rates of surgical intervention at two years.

At 12 months, approximately 20% of Mirena users achieve complete amenorrhea. By year two, that figure rises to roughly 35-40%. Kyleena, with its lower dose, produces amenorrhea in approximately 12% of users at one year, and irregular light spotting is more common than with Mirena.

The trade-off: the first three to six months after insertion can involve irregular spotting or even heavier-than-usual bleeding while the endometrium adapts. Many women are not warned about this clearly enough, and it drives early removal requests.

Side-by-Side Bleeding Summary

| Bleeding Pattern | Norethindrone (5 mg HMB dose) | Mirena LNG-IUD | Kyleena LNG-IUD | |---|---|---|---| | First 3 months | Irregular spotting common | Irregular spotting, possible heavier flow | Irregular spotting | | 6-12 months | Lighter periods, unpredictable | Significantly lighter; amenorrhea developing | Lighter but irregular | | 12+ months | Variable, cycle-dependent | ~20-40% amenorrhea | ~12% amenorrhea | | HMB reduction | Moderate | Large (NEJM 2013) | Moderate-large |

Systemic Side Effects: Mood, Libido, Skin, and Weight

Mood and Mental Health

Progestins and mood have a complicated relationship, and the research in women is thinner than it should be. Oral norethindrone, because it is fully systemic and crosses the blood-brain barrier, produces neuroactive metabolites. Some women report low mood, irritability, or anxiety within days of starting. This effect appears dose-dependent: the 5 mg HMB dose is more likely to cause mood symptoms than the 0.35 mg mini-pill dose.

A 2023 Danish registry study in over 1.2 million women found that hormonal contraception, particularly progestin-only pills, was associated with a higher rate of first antidepressant use compared with non-hormonal methods. The levonorgestrel IUD showed a smaller association than oral progestins in that analysis, consistent with its lower systemic exposure.

This does not mean the IUD is mood-neutral. Some women report mood changes with the LNG-IUD, particularly in the months immediately after insertion when systemic levels are highest. Clinicians should document mood at baseline before starting either method.

Libido and Sexual Health

Low libido is a reported side effect of both options, but the mechanism differs. NETA can suppress free testosterone (already often low in perimenopausal women) by increasing sex hormone-binding globulin (SHBG). This effect is well documented with oral progestins and oral estrogen combinations. The LNG-IUD raises SHBG to a much smaller degree because systemic absorption is so much lower.

If you are already dealing with hypoactive sexual desire disorder (HSDD) or low libido related to perimenopause, a systemic oral progestin carries a higher theoretical risk of worsening it than an IUD does. Direct comparative libido data in women on NETA versus LNG-IUD is limited. This is an area where clinicians are extrapolating from mechanism rather than from a head-to-head randomized trial, and you deserve to know that.

Acne, Hirsutism, and Skin

NETA's androgenic activity means that acne and, less commonly, increased facial hair are recognized side effects, especially at higher doses. Women with PCOS who already have androgen excess may find NETA worsens skin symptoms. The LNG-IUD, because systemic levels are so low, has minimal androgenic skin effects for most users. Mirena prescribing information lists acne as an adverse effect in roughly 6.8% of users, but clinical experience suggests this is more common in women predisposed to acne, and rates are lower than with oral NETA at therapeutic doses.

Weight Changes

Weight gain is frequently reported by women on both options, but the clinical evidence for a direct causal effect is weak for both. The Cochrane review on contraceptives and weight found insufficient evidence to conclude that progestin-only contraceptives cause weight gain. Changes in appetite and fluid retention are more plausible mechanisms than actual fat mass gain. NETA at HMB doses may cause more noticeable fluid retention than the LNG-IUD given the systemic exposure difference.

Female-Relevant Conditions: Which Option Fits Your Diagnosis?

PCOS

Women with PCOS often need endometrial protection without worsening androgen-driven symptoms (acne, hair loss, insulin resistance). NETA's mild androgenicity makes it a less ideal first choice if androgenic side effects are already a concern. The LNG-IUD offers excellent endometrial protection with less systemic androgen-receptor stimulation, making it generally preferable for PCOS-related endometrial hyperplasia prevention, though it provides no benefit for the metabolic features of PCOS.

Endometriosis

Both options are used off-label and on-label for endometriosis symptom management. NETA at 2.5 to 5 mg daily has randomized controlled trial support for pain reduction in endometriosis; a 2010 RCT by Vercellini et al. showed NETA 2.5 mg reduced endometriosis-related pain scores significantly versus placebo. The LNG-IUD reduces endometrial lesion activity locally and is supported by ACOG Practice Bulletin 114 as a management option. For endometriosis associated with deep infiltrating disease or ovarian endometrioma, a systemic agent may offer broader tissue reach.

Perimenopause and HRT Add-Back

This is one of the most common reasons a woman in her 40s or early 50s ends up comparing these two options. If you are on systemic estrogen for perimenopausal symptoms, you need a progestogen to protect the uterine lining. The Menopause Society (formerly NAMS) 2022 position statement supports both oral progestogens and the LNG-IUD as endometrial protection options in postmenopausal and perimenopausal women on systemic estrogen.

The LNG-IUD has the advantage of delivering endometrial protection locally while keeping systemic progestin exposure low, which may reduce mood and libido side effects from the progestogen component. NETA is familiar, inexpensive, and does not require a procedure. For women with fibroids, the LNG-IUD is generally preferred because it reduces heavy bleeding while providing protection; fibroids may rarely be displaced by insertion.

Heavy Menstrual Bleeding (HMB) Outside of HRT

If HMB is your primary concern and you are not on estrogen, the NEJM 2013 Gupta trial provides the clearest evidence: the LNG-IUS outperformed usual medical care (including oral progestins) on both blood loss and quality of life at two years. ACOG Practice Bulletin 128 lists the LNG-IUD as a first-line option for HMB management in women who want to preserve fertility.

Fibroids

Fibroids complicate IUD insertion. A significantly enlarged or distorted uterine cavity may prevent correct Mirena placement or increase expulsion risk. NETA can be used regardless of uterine anatomy. An ultrasound to assess cavity shape before IUD insertion is standard practice.

Pregnancy, Lactation, and Contraception Safety

Both options are contraindicated if pregnancy is confirmed. This section is required reading before starting either method.

Norethindrone in Pregnancy

NETA is a 19-nortestosterone derivative. At pharmacological doses, exposure in the first trimester carries a theoretical risk of virilization of a female fetus based on older animal and case data. The FDA labeling for norethindrone acetate classifies it as contraindicated in pregnancy. A pregnancy test should be done before initiating NETA at HMB doses (5 mg), particularly in perimenopausal women who may not recognize pregnancy risk.

Because NETA at the mini-pill dose (0.35 mg) is itself a contraceptive, it must be taken at the same time every day (within a three-hour window). Missing a pill by more than three hours requires backup contraception for 48 hours.

LNG-IUD in Pregnancy

The LNG-IUD is itself a highly effective contraceptive (failure rate <0.2% per year for Mirena). If pregnancy occurs with an IUD in place, the device should be removed as early as possible if the strings are visible, as in-situ IUDs carry increased risk of septic abortion, preterm birth, and pregnancy loss. There are no fetal teratogenicity data from properly conducted prospective studies of the LNG-IUD in ongoing pregnancies; the systemic dose is so low that fetal exposure would be minimal, but removal remains the recommended approach.

Lactation

Norethindrone (at mini-pill dose, 0.35 mg) is considered compatible with breastfeeding. It is the standard progestin-only pill recommended postpartum because it does not affect milk supply the way combined estrogen-progestin pills can. NETA at HMB doses (5 mg) transfers to breast milk at low levels; the LactMed database rates norethindrone as generally acceptable during lactation but notes that higher doses have not been as well studied as the 0.35 mg dose.

The LNG-IUD can be inserted four to six weeks postpartum. ACOG and CDC Medical Eligibility Criteria classify LNG-IUD use during breastfeeding as Category 1 (no restriction), meaning it is safe from six weeks postpartum onward. Systemic LNG exposure from the IUD is low enough that milk supply and infant are not meaningfully affected.

Contraception Reliability Comparison

| Method | Typical Use Failure Rate | Perfect Use Failure Rate | |---|---|---| | Norethindrone mini-pill (0.35 mg) | ~9% per year | ~0.3% per year | | Norethindrone at 5 mg (off-label contraceptive use) | Not established as standalone contraception | Not established | | Mirena LNG-IUD 52 mg | <0.2% per year | <0.2% per year | | Kyleena LNG-IUD 19.5 mg | <0.2% per year | <0.2% per year |

The LNG-IUD is significantly more reliable because it removes the user-dependent variable entirely.

Who This Is Right For, and Who Should Think Twice

Norethindrone Is Likely the Better Fit If You:

• Want a non-procedural option you can start and stop quickly
• Need an inexpensive generic with no upfront insertion cost
• Are in perimenopause and your clinician wants a simple HRT add-back that can be dose-adjusted
• Have endometriosis and need systemic progestin reach across multiple pelvic sites
• Have a uterine cavity distorted by fibroids that would complicate IUD placement
• Are not bothered by daily pill-taking

Norethindrone May Not Be the Right Fit If You:

• Already have mood instability, depression, or anxiety that worsens with systemic progestins
• Have significant androgen-related symptoms (acne, hirsutism) from PCOS
• Have low libido and want to minimize SHBG elevation
• Struggle with daily pill adherence

The LNG-IUD Is Likely the Better Fit If You:

• Have HMB as your primary complaint and want the most effective non-surgical option (NEJM 2013 data)
• Want highly reliable contraception without thinking about it daily
• Are sensitive to systemic progestin side effects (mood, libido, skin)
• Are in perimenopause on systemic estrogen and want low-systemic-exposure endometrial protection
• Are postpartum and breastfeeding (Category 1 from six weeks)
• Have PCOS and need endometrial protection without androgenic side effect concerns

The LNG-IUD May Not Be the Right Fit If You:

• Have a significantly distorted uterine cavity from fibroids or congenital anomaly
• Are not comfortable with a procedural insertion (though discomfort is usually brief)
• Have unexplained vaginal bleeding that has not yet been evaluated
• Have current or recent pelvic inflammatory disease (within the past three months)
• Are immunocompromised in a way that increases infection risk from insertion

Switching from Norethindrone to a Hormonal IUD (or Vice Versa)

Switching is straightforward in principle. If you are moving from norethindrone to an LNG-IUD, the IUD can typically be inserted at any point in your cycle if pregnancy has been reasonably excluded. Use backup contraception for seven days after insertion if you are relying on it for contraception and insertion did not occur within the first seven days of your cycle. You can stop norethindrone the day of or the day after insertion.

Moving from an LNG-IUD to norethindrone: start NETA immediately after removal if you want uninterrupted progestin coverage. For HRT add-back purposes, timing the switch to avoid a gap in endometrial protection matters more than for contraception.

One practical point: if your reason for switching is side effects, document which side effects specifically, because the expected profile change is predictable from the systemic-versus-local delivery difference outlined above. Switching from NETA to an IUD because of mood symptoms has biological rationale. Switching because of acne does too. Switching because of irregular bleeding is more nuanced: the early months after IUD insertion also involve irregular bleeding before settling.

"When a patient comes in unhappy with norethindrone side effects, I always ask first whether the problem is the progestin itself or the systemic route of delivery," says Rachel Goldberg, MD, WomanRx medical advisor. "If it's the route, the LNG-IUD often solves it. If the problem is any progestogen at all, we need a bigger conversation about whether she's a candidate for progesterone receptor modulators or endometrial ablation."

Evidence Gaps and What Is Still Unknown

Women have been consistently underrepresented in pharmacological trials, and this comparison is no exception.

No published head-to-head randomized controlled trial compares NETA oral therapy directly with the LNG-IUD for mood outcomes, libido, or skin changes in perimenopausal women specifically. The NEJM 2013 Gupta trial compared LNG-IUS to "usual medical care" as a bundle, not to NETA alone, so the HMB comparison is indirect. The 2023 Danish registry study on mood and hormonal contraception included LNG-IUD users but was observational, so confounding is possible.

Pharmacokinetic data in women across the menstrual cycle (how NETA is metabolized differently in the follicular versus luteal phase) remains sparse. Data on NETA at 5 mg in perimenopausal women with variable estrogen levels are extrapolated largely from reproductive-age HMB trials.

This means the side-effect comparison above reflects the best available synthesis of mechanism, indirect trial data, pharmacokinetic reasoning, and clinical experience. Where a direct RCT exists, it is cited. Where it does not, that is stated plainly.